IMMUNITYBIO INC (IBRX) Forecast, Price Target & Analyst Ratings

NASDAQ:IBRX • US45256X1037

Current stock price

7.25 USD
-0.53 (-6.81%)
At close:
7.25 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for IMMUNITYBIO INC (IBRX).

Forecast Snapshot

Consensus Price Target

Price Target
$15.10
+ 108.22% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.07
Revenue Estimate
44.032M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.45%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$15.10
Upside
+ 108.22%
From current price of $7.25 to mean target of $15.10, Based on 11 analyst forecasts
Low
$11.11
Median
$13.26
High
$24.15

Price Target Revisions

1 Month
15.63%
3 Months
42.31%

Price Target Summary

11 Wall Street analysts provided a forecast for the next 12 months for IBRX. The average price target is 15.1 USD. This implies a price increase of 108.22% is expected in the next year compared to the current price of 7.25.
The average price target has been revised upward by 42.31% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

IBRX Current Analyst RatingIBRX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 1 2 3 4 5

Analyst Ratings History

IBRX Historical Analyst RatingsIBRX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
85.45%
IBRX was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about IBRX.
In the previous month the buy percentage consensus was at a similar level.
IBRX was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-08D. Boral CapitalMaintains Buy -> Buy
2026-03-26D. Boral CapitalMaintains Buy -> Buy
2026-03-23D. Boral CapitalMaintains Buy -> Buy
2026-03-17D. Boral CapitalMaintains Buy -> Buy
2026-03-09D. Boral CapitalMaintains Buy -> Buy
2026-03-04Piper SandlerReiterate Overweight -> Overweight
2026-02-23D. Boral CapitalMaintains Buy -> Buy
2026-02-23HC Wainwright & Co.Maintains Buy -> Buy
2026-02-19D. Boral CapitalMaintains Buy -> Buy
2026-02-17D. Boral CapitalMaintains Buy -> Buy
2026-01-26HC Wainwright & Co.Maintains Buy -> Buy
2026-01-23D. Boral CapitalMaintains Buy -> Buy
2026-01-23BTIGMaintains Buy -> Buy
2026-01-20D. Boral CapitalMaintains Buy -> Buy
2026-01-20Piper SandlerMaintains Overweight -> Overweight
2026-01-16D. Boral CapitalMaintains Buy -> Buy
2026-01-13D. Boral CapitalMaintains Buy -> Buy
2025-12-16D. Boral CapitalMaintains Buy -> Buy
2025-12-12D. Boral CapitalMaintains Buy -> Buy
2025-12-12JefferiesMaintains Buy -> Buy
2025-12-11D. Boral CapitalMaintains Buy -> Buy
2025-11-13D. Boral CapitalMaintains Buy -> Buy
2025-11-05D. Boral CapitalMaintains Buy -> Buy
2025-09-10HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-08D. Boral CapitalMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
-$0.07
Revenue Estimate
44.032M
Revenue Q2Q
166.59%
EPS Q2Q
52.40%
Number of Analysts
7

Next Earnings Revisions

Revenue (1 Month)
0.89%
Revenue (3 Months)
9.98%
EPS (1 Month)
6.67%
EPS (3 Months)
12.50%

Next Earnings Summary

IBRX is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is -0.07 USD and the consensus revenue estimate is 44.03M USD.
The next earnings revenue estimate has been revised upward by 9.98% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
IBRX revenue by date.IBRX revenue by date.
622K
159.17%		14.745M
2,270.58%		113.288M
668.31%		213.65M
88.59%		493.86M
131.15%		1.234B
149.87%		2.187B
77.23%		3.716B
69.91%		6.06B
63.08%		7.977B
31.63%		10.486B
31.45%
EBITDA
YoY % growth
IBRX ebitda by date.IBRX ebitda by date.
-342.852M
-3.16%		-326.628M
4.73%		-240.502M
26.37%		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
YoY % growth
IBRX ebit by date.IBRX ebit by date.
-361.364M
-3.06%		-344.182M
4.75%		-256.027M
25.61%		-209.798M
18.06%		5.263M
102.51%		510.87M
9,606.82%		1.499B
193.42%		2.845B
89.79%		4.912B
72.65%		6.585B
34.06%		8.782B
33.36%
Operating Margin
IBRX operating margin by date.IBRX operating margin by date.
-58,097.11%-2,334.23%-226.00%-98.20%1.07%41.40%68.54%76.56%81.06%82.55%83.75%
EPS
YoY % growth
IBRX eps by date.IBRX eps by date.
-1.13
-7.62%		-0.61
46.02%		-0.38
37.70%		-0.26
31.28%		-0.06
78.13%		0.52
1,004.77%		1.25
141.77%		2.42
93.88%		4.14
70.95%		5.31
28.20%		6.95
30.84%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.07
52.40%		-0.07
32.68%		-0.07
6.74%		-0.05
15.00%		-0.07-0.07
-6.06%		-0.07
-9.38%		-0.06
-20.00%
Revenue
Q2Q % growth		44.032M
166.59%		49.129M
85.92%		55.483M
73.05%		65.067M
69.95%		62.016M
40.84%		67.32M
37.03%		72.726M
31.08%		86.802M
33.40%
EBITDA
Q2Q % growth		N/AN/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth		-59.063M
8.33%		-56.002M
21.44%		-54.314M
2.37%		-50.079M
22.58%		-44.509M
24.64%		-45.627M
18.53%		-41.236M
24.08%		-34.382M
31.34%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
49.78%
EPS Next 5 Year
52.97%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
120.55%
Revenue Next 5 Year
100.38%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

IMMUNITYBIO INC / IBRX Forecast FAQ

Can you provide the average price target for IMMUNITYBIO INC stock?

11 analysts have analysed IBRX and the average price target is 15.1 USD. This implies a price increase of 108.22% is expected in the next year compared to the current price of 7.25.

When does IMMUNITYBIO INC (IBRX) report earnings?

IMMUNITYBIO INC (IBRX) will report earnings on 2026-05-07.

What are the consensus estimates for IMMUNITYBIO INC (IBRX) next earnings?

The consensus EPS estimate for the next earnings of IMMUNITYBIO INC (IBRX) is -0.07 USD and the consensus revenue estimate is 44.03M USD.

Can you provide the expected long term growth rate for IMMUNITYBIO INC stock?

The expected long term growth rate for IMMUNITYBIO INC (IBRX) is 120.55%.